anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Forty subjects will be given either drug (atorvastatin 40 mg) or placebo in a randomized fashion once daily for six months. Using echocardiography, tonometry, and flow mediated dilation of conduit arteries and arterioles, baseline cardiovascular anatomy and physiology will be defined. Subjects that enroll in the study will be required to come in for 5 study visits. The initial visit is a screening visit; subject consent is obtained and an echocardiogram is performed as well as blood tests. At the randomization visit (4-14 days following screening), the subject will be provided with drug or placebo in a blinded fashion.Also at this visit, subjects will be asked to do a 6 minute walk, QOL questionnaire, and vascular function testing. There will be follow-up study visits at 1 and 3 months following randomization. At each follow-up visit a medical history, pill count and brief physical examination will be performed, a repeat QOL questionnaire administered, and blood tests to assess safety of the statin therapy. At 6 months, the final study visit will occur. At this visit a full history and detailed physical examination will be performed. Repeat echocardiogram, 6 minute walk test, QOL questionnaire, and vascular function examinations will be performed.
Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
PURPOSE: A composition and a cosmetic composition containing Amomi Cardamomi Fructus extract is provided to effectively prevent and treat lung cancer. CONSTITUTION: A composition for preventing and treating lung cancer contains Amomi Cardamomi Fructus ethanol extract as an active ingredient, prepared by extracting at 50 Deg. C. for 24 hours. The composition contains pharmaceutically acceptable carriers or diluents. The lung cancer is non-small cell lung cancer including adenocarcinoma, squamous cell carcinoma, or large cell carcinoma. A cosmetic composition for preventing lung cancer contains the extract as an active ingredient. [Reference numerals] (AA) Amomi Cardamomi Fructus
Mitogen-Activated Protein Kinases (MAPKs) are serine/threonine protein kinases that play a crucial role in transmitting extracellular signals to the intracellular environment, influencing a wide range of cellular processes including proliferation, differentiation, apoptosis, metabolic activities, immune function and stress response. MAPK4, a non-classical MAPK, is frequently overexpressed in various malignancies, including prostate, breast, cervix, thyroid, and gliomas. It orchestrates cell proliferation, migration, and apoptosis via the AKT/mTOR and/or PDK1 signaling pathways, thus facilitating tumor cell growth. Furthermore, MAPK4 expression is closely associated with the effectiveness of specific inhibitors like PI3K and PARP1, and also correlate with the survival rates of cancer patients. Increasing evidence highlights MAPK4's involvement in the tumor microenvironment, modulating immune response and inflammation-related diseases. This review comprehensively explores the structure, function, and oncogenic role of MAPK4, providing a deeper understanding of its activation and mechanisms of action in tumorigenesis, which might be helpful for the development of innovative therapeutic strategies for cancer management.
Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
The invention provides a Rhodotorula (Rhodotorula sp.) fg-23001, wherein the Rhodotorula fg-23001 is preserved in China general microbiological culture collection center (CGMCC) with the preservation number of 28218 and the preservation address in the year 08 and 23: no.1 and No. 3 of the north cinquefoil of the morning sun area of beijing city. The present invention also provides a microbial preparation comprising rhodotorula fg-23001 and/or a metabolite of rhodotorula fg-23001 as claimed in claim 1. The invention also provides a feed additive. The invention also provides an application of the rhodotorula fg-23001 in repairing intestinal mucosa injury of poultry. The invention also provides an application of the rhodotorula fg-23001 in preparing a microbial preparation or a feed additive for preventing and treating enteritis of poultry. The rhodotorula glutinis fg-23001 provided by the invention can effectively solve the problem of intestinal tract injury of broiler chickens caused by various factors, in particular to the symptom of diarrhea of animals caused by sudden temperature rising and falling, so that the intestinal mucosa falling-off symptoms of the animals can be effectively solved.
OBJECTIVES: The aim of this study is to compare the use of two different opioid delivery systems (bolus PCA with/without basal infusion) to control postoperative pain and evaluate the side effect profile in pediatric patients undergoing scoliosis surgery.
PATIENTS AND METHODS: 38 patients who underwent posterior spinal fusion for adolescent idiopathic scoliosis were included in the study. Patients were randomly divided into 2 groups by the computer. Patients who received only bolus PCA were named Group 1, and patients who received bolus PCA with basal infusion were named Group 2.Morphine consumption, postoperative pain assessmentduring rest, movement and coughing with numeric rating scale (NRS) and the Wong -Baker pain scale, heart rate and average blood pressure, sedation levels withRamsey sedation scale and side effects such as nausea, vomiting, itching, desaturation, and urinary retention were recorded.
RESULTS: Total mean morphine consumption (mg) was 32.7 ± 9.7 in Group 1 and 43.4 ± 9.1 in Group 2. The mean morphine consumption (mg) at 12-24 hours and 0-48 hours in Group 1 was statistically lower than Group 2 (p = 0.001). There was no significant difference between the groups in terms of median NRS scores (p = 0.55). There was no statistically significant difference in the evaluation of the groups in terms of Wong-Baker pain scale. Wong-Baker pain scale is p:0.66 at the 2nd hour, p:0.951 at the 12th hour and p:0.467 at the 24th hour.There was no statistically significant difference in Ramsay Sedation Scale evaluation between groups during each follow-up time (p > 0.05). The Ramsay Sedation Scale was p: 0.94 at the 2nd hour, p:1.0 at the 12th hour, and p:1.0 at the 24th hour. The duration of vomiting between 0-2 h, 2-24 h and 0-48 h was higher in Group 2 (p = 0.001, p = 0.024, p = 0.001).
CONCLUSION: The two administration settings of morphine sulphate by PCA pump have shown to be equally effective in the treatment of postoperative pain following PSF. In addition, PCA with basal infusion administration causes more opioid consumption and more systemic side effects. Therefore, the use of only bolus PCA in pediatric scoliosis surgery should be encouraged.
LEVEL OF EVIDENCE: Level II, Randomized Controlled Trial.
INTRODUCTION: Patients with relapsed/refractory (r/r) acute T-lymphoblastic leukemia (T-ALL) have a poor prognosis. We developed donor CD7 chimeric antigen receptor T (CAR-T) cells to salvage r/r T-ALL patients and obtained encouraging results. Patients who had not received allogeneic (allo-) hematopoietic stem cell transplantation (HSCT) before CAR-T therapy would develop pancytopenia and immunodeficiency for a long period after CD7 CAR-T therapy; therefore, allo-HSCT is needed in these patients. Here, we report two pediatric r/r T-ALL patients who received donor CD7 CAR-T bridging to allo-HSCT with leukemia-free survival (LFS) and sustained negative minimal residual disease for >2 years.
CASE PRESENTATION: Patient 1 was a 10-year-old boy who visited our hospital because of a T-ALL relapse with multiple lymphadenopathies without discomfort. The patient did not achieve remission after one course of induction chemotherapy. The patient then received donor (his father) CD7 CAR-T cells and achieved complete remission (CR). Thirty days after the first CAR-T cell infusion, he received allo-HSCT, and his father was also the donor. His LFS was >3 years. Patient 2 was an 8-year-old boy who was admitted to our hospital with relapsed T-ALL with fever, cough, and mild dyspnea. He did not achieve remission after one course of induction chemotherapy; therefore, he received donor (his father) CD7 CAR-T cells and achieved CR. Twenty-six days after CAR-T cell infusion, the patient received allo-HSCT, with his father as the donor. He has survived for >2 years free of leukemia. At the last follow up, both patients were alive and presented a good quality of life.
CONCLUSION: The long-term survival of these two patients supports the use of CD7 CAR-T therapy bridging to allo-HSCT as an effective and safe treatment with the capacity to make r/r T-ALL a curable disease, similar to r/r acute B-lymphoblastic leukemia.
The invention provides nerve soothing incense. The nerve soothing incense comprises perfume, adhesive and accessories and is prepared from, by weight, 5-10 parts of rhizoma acori graminei, 5-10 parts of sandalwood, 1-3 parts of coptis chinensis, 4-8 parts of radix paeoniae alba, 1-5 parts of cortex albiziae, 1-3 parts of valerian roots, 1-3 parts of concretio silicea bambusae, 4-8 parts of ganoderma, 5-10 parts of tuber fleeceflower stems, 10-15 parts of radix curcumae, 4-9 parts of acronychia pedunculata, 5-10 parts of cyperus rotundus, 4-9 parts of platycladi seeds, 1-5 parts of aquilaria sinensis, 1-3 parts of yellow ripe incense, 40-50 parts of bletilla striata, 10-15 parts of dextrin, 3-5 parts of charcoal, 1-3 parts of bark of aidia canthioides (Champ. ex Benth.) Masam., 5-10 parts of honey and 5-10 parts of rosin. A preparation method comprises the steps that the perfume, the charcoal and the bark of aidia canthioides (Champ. ex Benth.) Masam. are smashed and mixed with the rosin, the dextrin and the honey which are heated and molten, the mixture is prepared into incense strips or incense sheets, and the finished product is obtained through drying and packaging and is stored. The nerve soothing incense has the advantages that the raw materials are purely natural, no chemical additive is added, and making is easy; the prepared incense can soothe the nerve, dredge the healthy atmosphere of the human body and regulate the body balance.
Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.
There is a pressing need for improved acute care setting suicide prevention interventions. The Safety Planning Intervention (SPI) is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings (i.e., emergency departments (ED) and inpatient units). The SPI involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis. It is easy to learn and administer, acceptable to patients, brief, firmly rooted in an empirical base and has preliminary studies supporting its feasibility and potential to impact patient outcomes, including suicidal behavior and treatment engagement. However, while it is being adopted widely, it lacks a randomized controlled trial (RCT) to definitively determine its efficacy. The purpose of this study to conduct a randomized control trial of the Safety Planning Intervention (SPI) compared with receiving risk factors and warning sign information (RWI) in acute care settings.

All participants in this study will complete some baseline assessments, following which they will be randomly assigned to one of two study conditions: Safety Plan Intervention (SPI) or receiving risk factors and warning sign information (RWI). If assigned to SPI, participants will receive the assigned intervention by the research clinician. They will receive a paper copy of their safety plan while in the ED or on the inpatient unit and a back-up copy will be sent approximately 1 week after discharge to participants. For RWI participants, ED and inpatient unit care will be delivered as usual, with the addition of a printed information sheet listing suicide risk factors and crisis hotlines. In addition to the baseline assessment, multi-method outcome assessment will be conducted at 1, 3, and 6 months. This will include telephone evaluations by a blinded assessor (not the research clinician), medical record review, and vital statistics registry review.
A therapy adjustment received from a patient is associated with a sensed patient posture state. Thereafter, a stability indication can be associated with the sensed posture state to indicate that a therapy adjustment specific to the sensed posture state was received and implemented. In addition, therapy parameter values associated with related patient posture states are updated based on the therapy adjustment. In some examples, only the related posture states that are not associated with respective stability indications are updated based on the therapy adjustment. The absence of a stability indication indicates that the patient has not inputted a therapy adjustment specific to the respective related posture state. As a result, the therapy parameter values associated with the related posture states that are not associated with stability indications may float until the patient adjusts the therapy parameter value associated with the respective related posture state.
Approval to perform this study was granted by the Rockhurst University Institutional Review Board (IRB) and the Rockhurst University (RU) Occupational Therapy Department prior to participant recruitment. Written informed consent was obtained from the parents of the participants and physical assent was obtained from the children older than 8 years of age. Researchers were trained by the primary investigator following an established written protocol for eye gaze technology administration. The protocal involved set up of the eye gaze camera and laptop computer with calibration of the camera to the child's eyes using Gaze Point software by Tobii. If the camera is unable to be calibrated to the child's eyes it will be calibrated with the therapists eyes in the same position as the child with eyes centered in the middle of the calibration screen. The child will be positioned 15-18 inches from the screen with a black trifold board behind the screen and lights turned off in a quiet room to decrease distractions. Teachers and therapists involved with data collection were trained in eye gaze technology administration following the protocal. Data was collected by the Insight and Learning Curve eye gaze software using percentage scoring and a heat map/line plot pictures. Eye gaze technology sessions will last 20 minutes, three to five days per week, for four weeks. Images presented during the eye gaze sessions include the following characteristics: single colors, reduced complexity, movement of the image, reduced surrounding auditory and visual clutter, and reduced inclusion of multiple colors. Demographic information, Canadian Occupational Performance Measurement (COPM,) Cortical Visual Impairment (CVI) Range, Sensory Profile Short Form (SP), and Sensory Processing Checklist for Children with Visual Impairment (SPCCVI) scores were collected by the researchers prior to administration of the eye gaze intervention. A baseline score was obtained from the Insight software using a mean of the subtests completed and then a mean of the subtests 4 weeks later. Scores for all of the measures except for the Sensory Profile and SPCCVI were then re-collected 4 weeks later at the conclusion of the study. Data was compiled and stored on a file on a password protected computer.
PURPOSE: To make efficient treatment of the high liquid pressure of the eyes by using and applying the clathrate complex of a prostaglandin compd. (salt) and cyclodextrin capable of lowering the intra-ocular pressure in and to prepn. of a compd. for the eyes. CONSTITUTION: The treatment of the high liquid pressure of the eyes is executed by using the clathrate complex of the prostaglandin compd. selected from a group consisting of >=1 kinds of PGE2 , PGE2 d, their derivatives and pharmaceutically permissible salts capable of lowering the intra-ocular pressure and the cyclodextrin selected from a group consisting of one or more kinds of α-, β- and γ-cyclodextrins in the prepn. of the compd. for the eyes and applying the complex to the eyes in the amt. effective for the treatment. The compd. for the eyes is preferably an aq. soln. contg. 0.001 to 5% (W/V) cyclodextrin compd. (salt).
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Appropriate weight gain goals promote healthy gestational weight gain (GWG). Despite receiving recommendations from their providers, most women do not know how much weight they should gain during pregnancy. This study sought to describe the experiences of pregnant women when given GWG recommendations. The research proceeded using a phenomenological approach. With Institutional Review Board approval, primigravida women with a healthy singleton pregnancy at 8-20 weeks gestation were recruited from the community and purposively from a low-income obstetrics clinic. Within 60-minutes, trained interviewers 1) presented GWG recommendations and associated risks; and 2) interviewed participants using a semi-structured guide. Participants received a $40 gift card. Interviews were recorded and transcribed. Two trained coders used Braun and Clarke's (2020) reflexive thematic analysis procedures. When presented with GWG information, participants (n = 29, Mage = 25.5, 4.7 SD) proceeded to: 1) make sense of the information, 2) evaluate the credibility of the information, 3) weigh the importance of the information, 4) predict likely outcomes, and 5) plan behaviors. Participants who were able to understand the information, found it to be credible and important, and who predicted adverse outcomes for failing to adhere to recommendations reported intentions for health promoting behaviors. Future research should test GWG counseling methods based on these cognitive processes. Clinicians should consider these 5 cognitive processes when providing initial GWG counseling.
FIELD: medicine, veterinary science. SUBSTANCE: invention relates to anthelmintic agent comprising of albendazol and copper complex as an active substance that is enclosed in microcapsules making of acetylcellulose in the ratio of albendazole, copper sulfate and acetylcellulose = 1:1:0.5, respectively. Insertion of albendazole metal complex in anthelmintic agent composite allows to enhance therapeutic activity and inclusion of albendazole metal complex in microcapsule made of acetylcellulose provides the prolonged end effect that is necessary for radical chemotherapy of larval echinococcosis. Agent provides the complete inhibition of growth of exhinococcus larvocysts and death of all population of parasite. EFFECT: enhanced effectiveness of agent. 1 cl, 3 tbl, 3 ex
G2 132 parents in charge of children and adolescents with and without SRBDs who will answer the final version of the protocol. This group will include 66 parents in charge of participants with SRBDs and 66 parents in charge of participants without SRBDs.
Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
Over 120 million Americans report experiencing pain in the past 3 months. Among these individuals, 50 million report chronic pain and 17 million report pain that limits daily life or work activities on most days (ie, high-impact chronic pain). Musculoskeletal pain conditions in particular are a major contributor to global disability, health care costs, and poor quality of life. Movement-evoked pain (MEP) is an important and distinct component of the musculoskeletal pain experience and represents an emerging area of study in pain and rehabilitation fields. This focus article proposes the "Pain-Movement Interface" as a theoretical framework of MEP that highlights the interface between MEP, pain interference, and activity engagement. The goal of the framework is to expand knowledge about MEP by guiding scientific inquiry into MEP-specific pathways to disability, high-risk clinical phenotypes, and underlying individual influences that may serve as treatment targets. This framework reinforces the dynamic nature of MEP within the context of activity engagement, participation in life and social roles, and the broader pain experience. Recommendations for MEP evaluation, encompassing the spectrum from high standardization to high patient specificity, and MEP-targeted treatments are provided. Overall, the proposed framework and recommendations reflect the current state of science in this emerging area of study and are intended to support future efforts to optimize musculoskeletal pain management and enhance patient outcomes. PERSPECTIVE: Movement-evoked pain (MEP) is a distinct component of the musculoskeletal pain experience and emerging research area. This article introduces the "Pain-Movement Interface" as a theoretical framework of MEP, highlighting the interface between MEP, pain interference, and activity engagement. Evaluating and treating MEP could improve rehabilitation approaches and enhance patient outcomes.